These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36154278)

  • 1. Keeping up the 'race pace' in a patient with nonuterine leiomyosarcoma.
    Szkandera J
    Future Oncol; 2022 Sep; 18(29s):12-16. PubMed ID: 36154278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.
    Turinetto M; Meeus P; Ray-Coquard I
    Curr Opin Oncol; 2023 Jul; 35(4):288-291. PubMed ID: 37222199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Saada-Bouzid E; Bertucci F; Bompas E; Alexandre J; Collard O; Lebrun-Ly V; Soulier P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    ESMO Open; 2021 Aug; 6(4):100209. PubMed ID: 34325109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An Effective Treatment of Relapsed Leiomyosarcoma with Fourth-Line Trabectedin].
    Nozaki Y; Yamaguchi S; Takagi T; Kato S
    Gan To Kagaku Ryoho; 2019 Feb; 46(2):275-277. PubMed ID: 30914533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
    Galizia D; Palesandro E; Nuzzo AM; Pignochino Y; Aliberti S; Aglietta M; Grignani G
    Oncol Res; 2013; 20(10):483-90. PubMed ID: 24308159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
    Tavella K; Villanucci A; Vannini L; Lavacchi D; Montelatici S; Amunni G; Mazzei T
    Anticancer Drugs; 2017 Apr; 28(4):465-468. PubMed ID: 28181940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
    Jones RL; Maki RG; Patel SR; Wang G; McGowan TA; Shalaby WS; Knoblauch RE; von Mehren M; Demetri GD
    Cancer; 2019 Dec; 125(24):4435-4441. PubMed ID: 31503332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Time Progression-Free Survival with Trabectedin in Chemorefractory Metastatic Leiomyosarcoma of the Retroperitoneum: A Case Report.
    Reichinger A
    Case Rep Oncol; 2023; 16(1):1013-1019. PubMed ID: 37900801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
    Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.
    Aliberti S; Miano S; Tolomeo F; Merlini A; Aglietta M; Grignani G
    Future Oncol; 2020 Jan; 16(1s):15-19. PubMed ID: 31916842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
    Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A
    Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Jones RL; Demetri GD; Schuetze SM; Milhem M; Elias A; Van Tine BA; Hamm J; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Patel S; von Mehren M
    Ann Oncol; 2018 Sep; 29(9):1995-2002. PubMed ID: 30084934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
    Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
    J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Patel S; von Mehren M; Reed DR; Kaiser P; Charlson J; Ryan CW; Rushing D; Livingston M; Singh A; Seth R; Forscher C; D'Amato G; Chawla SP; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Demetri GD
    Cancer; 2019 Aug; 125(15):2610-2620. PubMed ID: 31173362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
    Matsuda S; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    Medicine (Baltimore); 2020 Jan; 99(2):e18689. PubMed ID: 31914068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
    Ray-Coquard I
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S3-5. PubMed ID: 21540667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
    Shamai S; Merimsky O
    Isr Med Assoc J; 2018 Oct; 20(10):599-603. PubMed ID: 30324774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Progression-Free Survival in a Patient with Metastatic Leiomyosarcoma of the Inguinal Region Treated with Trabectedin.
    Haslbauer F
    Case Rep Oncol; 2018; 11(1):246-251. PubMed ID: 29805376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.